Fulgent Genetics (FLGT) Equity Average (2016 - 2026)

Fulgent Genetics has disclosed Equity Average across 11 years of filings, most recently posting $1.1 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $1.1 billion, down 4.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 4.25% YoY), and the FY2025 annual result was $1.1 billion, down 0.94% from the prior year.
• Equity Average came in at $1.1 billion for Q1 2026 at Fulgent Genetics, down from $1.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.3 billion in Q2 2022 to a low of $1.1 billion in Q1 2026.
• The 5-year median for Equity Average is $1.1 billion (2024), against an average of $1.2 billion.
• Across the five-year window, Equity Average soared 80.81% in 2022 and declined 10.98% in 2024, its largest moves.
• Fulgent Genetics' Equity Average stood at $1.3 billion in 2022, then slipped by 6.12% to $1.2 billion in 2023, then fell by 5.47% to $1.1 billion in 2024, then dropped by 1.38% to $1.1 billion in 2025, then declined by 3.43% to $1.1 billion in 2026.
• The last three Equity Average figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.